{"id":"NCT05282004","sponsor":"Sandoz","briefTitle":"Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit","officialTitle":"An Open-label, Single-arm, Multicenter Study in Patients With Neovascular Age-related Macular Degeneration to Evaluate the Safety of SOK583A1 (40 mg/mL), a Proposed Aflibercept Biosimilar Product, Provided in a Vial Kit","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-05-16","primaryCompletion":"2022-09-07","completion":"2022-09-07","firstPosted":"2022-03-16","resultsPosted":"2023-05-10","lastUpdate":"2023-05-10"},"enrollment":36,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular Age-related Macular Degeneration (nAMD)"],"interventions":[{"type":"DRUG","name":"SOK583A1","otherNames":[]}],"arms":[{"label":"SOK583A1","type":"EXPERIMENTAL"}],"summary":"This is a single-arm, open-label study where all patients will receive a single injection of SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the individual participant is approximately 31 days.","primaryOutcome":{"measure":"Number of Participants With Ocular Treatment Emergent Adverse Events","timeFrame":"31 days","effectByArm":[{"arm":"SOK583A1 40 mg/mL","deltaMin":16,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":36},"commonTop":["Intraocular pressure increased","Conjunctival haemorrhage","Vitreous floaters","COVID-19"]}}